Open to all ACG 2019 attendees, industry-sponsored satellite symposia provide additional educational opportunities for attendees. These programs are independent of the ACG 2019 Annual Scientific Meeting & Postgraduate Course and ACG is not the continuing medical education provider for these programs.
Industry-sponsored satellite symposia provide additional educational opportunities for attendees. These programs are independent of the ACG 2019 Annual Scientific Meeting and Postgraduate Course programs. The ACG is not the continuing medical education provider of these programs. Unless otherwise noted, all symposia will take place at the Grand Hyatt San Antonio. For more information, see the company sponsor.
FRIDAY, OCTOBER 25
Why Eosinophilic Esophagitis Should Be on Your Radar: Experts Weigh In
Evan S. Dellon, MD, MPH, FACG, Ikuo Hirano, MD, FACG, Joel E. Richter, MD, MACG
5:30 pm - 7:30 pm | Texas Ballroom A
Drs Hirano, Dellon, and Richter review the diagnosis and treatment of EoE in this engaging, interactive live symposium.
Supported by an independent educational grant from Shire.
NASH: An Evolving Landscape of Opportunities
Kenneth Cusi, MD, Ira M. Jacobson, MD, FACG, Zobair M. Younossi, MD, MPH, FACG
7:30 pm - 9:30 pm | Texas Ballroom A
Drs Younossi, Cusi, and Jacobson will discuss how to improve rates of diagnosis of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) so that they can receive appropriate treatment.
Supported by an independent educational grant from Intercept Pharmaceuticals, Inc.
SATURDAY, OCTOBER 26
Application to Practice: Translating the New Ulcerative Colitis Guidelines for the Optimal Management of Your Patients with UC
David T. Rubin, MD, FACG, Millie D. Long, MD, MPH, FACG
5:30 pm - 7:30 pm | Lone Star Ballroom ABC
Clinicians caring for patients with ulcerative colitis must be aware of how the management of UC is evolving. With the increasing number of treatment choices for patients with UC, real- world effectiveness and clinical trials data may facilitate the identification of the right treatment for the right patient. Additionally, the UC management paradigm has shifted from clinical remission mainly based on symptoms to objective parameters such as endoscopic healing. This CME Outfitters interactive symposium will feature expert faculty presenting real-world cases that illustrate challenges, knowledge and practice gaps, application of principles to practice and how best to incorporate them into practice. For more information about this program, click here.
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Addressing GI Bleeds and Mitigating Risk: Focus on DOAC Reversal and Unanswered Questions
Sunguk Jang, MD, Noam Z. Drazin, MD, Yen-TeChristian Tu, MD
5:30 pm - 7:30 pm | Texas Ballroom AB
This symposium focuses on GI bleeding events and obstacles to effective care of patients with
severe GI bleeding that are on DOACs. The activity will also cover: Identification of risk factors for severe GI bleeding among patients on DOACs, review of DOAC reversal agents, and integration of tools for cross-disciplinary communication and coordination into real-world treatment plans for patients with severe GI bleeding. For more information about this program, click here.
This activity has been supported through an independent educational grant from Portola Pharmaceuticals, Inc.
Mucosal Healing as the Goal for Crohn’s Disease Treatment: Discovering Strategies for Therapeutic Success
Miguel D. Regueiro, MD, FACG, Russell D. Cohen, MD, FACG, Corey A. Siegel, MD, MS
7:30 pm - 9:30 pm | Texas Ballroom DE
Review the evidence in support of MH as a primary goal of CD treatment; Discuss strategies to define, monitor, and achieve MH in patients with moderate-to-severe CD; Evaluate the clinical trial data and RWE surrounding the impact of available biologics on MH induction and maintenance for optimal therapeutic positioning.For more information about this program, click here.
The following company has provided an educational grant in support of this symposium: Takeda Pharmaceuticals U.S.A, Inc.
GIs Discuss Megatrends of the Future: A Discussion on the microbiota, emerging trends and more, as revealed by a survey of 500 specialists
7:30 pm - 9:30 pm | Lone Star Ballroom EF
Join us for a Salix Anniversary celebration featuring a panel presentation of recent survey findings on what gastroenterologists think the future holds for the specialty. Topics covered by industry thought leaders will include the gut microbiota, Fecal Microbiota Transplantation (FMT), big data, artificial intelligence, telemedicine, and more.
This Satellite Symposium is sponsored by Salix Pharmaceuticals.
SUNDAY, OCTOBER 27
Trial By Jury: Irritable Bowel Syndrome
Brooks D. Cash, MD, FACG, Lin Chang, MD, FACG, William D. Chey, MD, FACG, David C. Kunkel, MD, Mark Pimentel, MD, FACG
5:30 am - 7:30 am | Lone Star Ballroom ABC
On-site registration is available. Space is limited, so please arrive by 5:45 am. Seating is on a first- come, first-served basis.
For more information about this program, click here.
Supported by an educational grant from Salix Pharmaceuticals.
An Updated Clinical Overview of a Prescription Treatment for Patients With Moderately to Severely Active Ulcerative Colitis
Anita Afzali, MD, MPH, FACG
7:30 pm - 9:30 pm | Texas Ballroom ABC
Dr. Anita Afzali will discuss the clinical data and safety profile for a nonbiologic prescription treatment for adult patients with moderately to severely active UC.
This event is sponsored by Pfizer.
The Many Faces of Abdominal Pain: Distinguishing Between Common and Uncommon Causes
William D. Chey, MD, FACG, Sean R. Rudnick, MD
7:30 pm - 9:30 pm | Lone Star Ballroom F
During this dinner program, you will test your diagnosis skills with two patient cases with unexplained abdominal pain including laboratory, radiographic, and other findings; and learn how to distinguish among some of the various causes of abdominal pain that can present in clinical practice. Drs. William Chey and Sean Rudnick will hold a question and answer period to close the program.
This program is sponsored by Alnylam Pharmaceuticals.
MONDAY, OCTOBER 28
Mucosal Healing and Steroid-Free Remission in Ulcerative Colitis: What is the Role of Current and Emerging Treatments?
Miguel D. Regueiro, MD, FACG, David T. Rubin, MD, FACG
5:30 am - 7:30 am | Texas Ballroom D
This CME Outfitters symposium features expert faculty in an interactive discussion utilizing real-life case scenarios to highlight optimal approaches to treat and monitor patients with UC. For more information about this program, click here.
Supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and Genentech.
Seeing is Believing: Why Colonoscopy is the Gold Standard
David A. Johnson, MD, MACG, Douglas K. Rex, MD, MACG, James P. Clancy, MD
7:00 pm - 9:00 pm | Lone Star Ballroom AB
The goal of this activity is to educate health care professionals about the use of appropriate CRC screening methods, including the limitations and advantages of both colonoscopic and non- colonoscopic approaches. For more information about this program, click here.
This activity is jointly provided by Global Education Group and Applied Clinical Education. This activity is supported by an educational grant from Braintree, A Part of Sebela Pharmaceuticals.
The Emerging Role of the Gut Microbiome in Reducing Recurrence of C. difficile Infection
Paul Feuerstadt, MD, FACG, Sahil Khanna, MBBS, MS, Gautam Mankaney, MD
7:00 pm - 9:00 pm | Texas Ballroom A
At this CME activity the faculty will conduct a roundtable symposium on recurrent C. difficile infection, including its etiology and burden, risk factors, the role of the gut microbiome, guideline- directed therapy, and new and emerging choices to reduce recurrent infection. The panel will also present patient cases of recurrent infections to discuss application of current guidelines and clinical trial data on emerging treatments. For more information about this program, click here.
Sponsored by the Academy for Continued Healthcare Learning (ACHL). This activity is supported by an educational grant from Ferring Pharmaceuticals, Inc.
TUESDAY, OCTOBER 29
Intercept Corporate Engagement
7:00 pm - 9:00 pm | Lone Star Ballroom AB
Intercept Pharmaceuticals invites you to join us! As we continue to work towards building a healthier tomorrow for patients with progressive non-viral liver diseases, we want to use this opportunity to better connect with our industry providers and share some exciting updates.
This event is sponsored by Intercept Pharmaceuticals.